We have recently demonstrated that functional systemic CD4 T cell immunity is required for a clinical response to immune checkpoint inhibitors in NSCLC patients who had progressed to platinum-based chemotherapy [8]. This evidence concerns the gene CD4 and non-small cell lung carcinoma.